Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective – A systematic review of recently published literature on real-world data

Гартнер, Барбара; Weinke, Thomas; Wahle, Klaus W.J.; Kwetkat, Anja; Beier, Dietmar; Schmidt, K J; Schwarz, Tino F.

doi:10.1016/j.vaccine.2022.04.019

Cited by 24 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The addition of the adjuvant AS01 in the vaccine formulation for herpes zoster virus increases the number of CD4 + T cells in older individuals [ 151 ]. A systematic review from 2022 suggests that adjuvanted influenza vaccines are preferable over conventional vaccines for older individuals [ 152 ]. MF59 and AS03 adjuvants have been used for influenza vaccines for older adults with great effectiveness [ 153 ].…”

Section: Strategies To Reverse Immunosenescence Of Adaptive Immunity ...mentioning

confidence: 99%

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells

Garnica

Aiello

Ligotti

et al. 2022

IJMS

View full text Add to dashboard Cite

The number of people that are 65 years old or older has been increasing due to the improvement in medicine and public health. However, this trend is not accompanied by an increase in quality of life, and this population is vulnerable to most illnesses, especially to infectious diseases. Vaccination is the best strategy to prevent this fact, but older people present a less efficient response, as their immune system is weaker due mainly to a phenomenon known as immunosenescence. The adaptive immune system is constituted by two types of lymphocytes, T and B cells, and the function and fitness of these cell populations are affected during ageing. Here, we review the impact of ageing on T and B cells and discuss the approaches that have been described or proposed to modulate and reverse the decline of the ageing adaptive immune system.

show abstract

Section: Strategies To Reverse Immunosenescence Of Adaptive Immunity ...mentioning

confidence: 99%

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells

Garnica

Aiello

Ligotti

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…STIKO preferentially recommended the use of QIV-HD in those aged 60 years and above [14,15] based on the results of a randomized controlled trial (RCT) comparing the trivalent version of the high-dose vaccine to the standard-dose trivalent vaccine [9]. While there are no RCTs comparing aTIV and TIVe, multiple studies of real-world effectiveness have been published [12,16]. Standard or adjuvanted influenza vaccines would not be covered by statutory health insurance (SHI), given the preferential recommendation for QIV-HD by STIKO and its adoption by the G-BA (Gemeinsamer Budesausschuss or Federal Joint Committee).…”

Section: Introductionmentioning

confidence: 99%

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany

Kohli¹,

Maschio²,

Cartier³

et al. 2022

Vaccines

View full text Add to dashboard Cite

Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of antigen (QIV-HD), which stimulate a stronger immune response in older adults than the standard vaccine (QIVe), are now approved. The objective of this research is to compare available vaccines and determine the cost-effectiveness of immunizing persons aged 65 years and above with aQIV compared to QIVe and QIV-HD in Germany. A compartmental transmission model calibrated to outpatient visits for influenza in Germany was used to predict the number of medically attended infections using the three vaccines. The rates of hospitalizations, deaths, and other economic consequences were estimated with a decision tree using German data where available. Based on meta-analysis, the rVE of −2.5% to 8.9% for aQIV versus QIV-HD, the vaccines are similar clinically, but aQIV is cost saving compared to QIV-HD (unit cost of EUR 40.55). All results were most sensitive to changes in vaccine effectiveness. aQIV may be cost-effective compared to QIVe depending on the willingness to pay for additional benefits in Germany. As aQIV and QIV-HD are similar in terms of effectiveness, aQIV is cost saving compared to QIV-HD at current unit prices.

show abstract

“…Wichtigkeit von "Real-World"-Daten (RWD) Daten aus RCTs sind für die Bewertung und Zulassung von Impfstoffen unerlässlich. Die Wirksamkeit unter Laborbedingungen entspricht jedoch nicht immer vollständig der Effektivität in der realen Welt, da sie sowohl von Virusfaktoren als auch Wirtsfaktoren wie Alter (Immunseneszenz), Komorbiditäten (einschließlich Gebrechlichkeit), vorheriger Exposition und vorheriger Impfung stark beeinflusst wird [25]. Seit Beginn der COVID-19-Pandemie haben "Real-World"-Daten (RWD) aus Beobachtungsstudien an großer Bedeutung gewonnen.…”

Section: Impfoptionen Für äLtere Erwachsene In Deutschlandunclassified

“…Ein neuer systematischer Literaturreview identifizierte 11 Analysen aus 9 Beobachtungsstudien, die rund 53 Mio. ältere Erwachsene und 12 Saisons umfassten [25]. Der Review fand eine statistisch signifikante relative Impfeffektivität (rVE) zugunsten von adjuvantiertem trivalenten Impfstoff (aTIV) vs. herkömmliche Impfstoffe in Bezug auf influenzaassoziierte Endpunkte in 9 Analysen (rVE: 6,5-33 %).…”

Section: Neue Evidenz Aus Beobachtungsstudienunclassified

Weiterentwickelte zielgruppenorientierte Influenzaimpfstoffe – Neue Evidenz zeigt höhere Effektivität bei älteren Erwachsenen

Frühwein

Schelling

Wahle

et al. 2023

Dtsch Med Wochenschr

View full text Add to dashboard Cite

ZusammenfassungDie saisonale Influenza verursacht eine signifikante Krankheitslast in der deutschen Bevölkerung und geht mit hohen volkswirtschaftlichen Kosten einher. Personen ab 60 Jahren sind aufgrund von Immunseneszenz und chronischen Erkrankungen besonders gefährdet und machen einen Großteil der influenzaassoziierten Hospitalisierungen und Todesfälle aus. Adjuvantierter, Hochdosis-, rekombinanter und zellbasierter Influenzaimpfstoff wurden entwickelt, um die Effektivität im Vergleich zu herkömmlichen Impfstoffen zu verbessern. Neueste Beobachtungsstudien zeigen eine bessere Effektivität des adjuvantierten Impfstoffs gegenüber herkömmlichen Impfstoffen und eine ähnliche Effektivität wie der Hochdosis-Impfstoff bei älteren Erwachsenen. Einige Länder berücksichtigten die neue Evidenz bereits in ihren Impfempfehlungen für die aktuelle oder frühere Saisons. Auch in Deutschland sollte die Verfügbarkeit der Impfstoffe für ältere Erwachsene sichergestellt sein, um einen hohen Impfschutz zu garantieren.

show abstract

Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective – A systematic review of recently published literature on real-world data

Cited by 24 publications

References 27 publications

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany

Weiterentwickelte zielgruppenorientierte Influenzaimpfstoffe – Neue Evidenz zeigt höhere Effektivität bei älteren Erwachsenen

Contact Info

Product

Resources

About